Merck and Sanofi didn’t just “cut prices” through TrumpRx—they helped test whether America can pressure Big Pharma into lower costs without letting Washington set the price tag.
Quick Take
- Merck and Sanofi joined a growing TrumpRx roster that aims to sell select brand-name drugs at steep discounts through a direct-to-consumer platform.
- The deals pair consumer-facing discounts with “most favored nation” pricing commitments tied to Medicaid, pushing U.S. prices closer to what other rich countries pay.
- Headline cuts look dramatic—like Merck’s Januvia dropping to about $100 and Sanofi listing some insulin at $35/month—but the fine print and drug selection matter.
- TrumpRx signals a challenge to the middleman economy in U.S. drug pricing, especially pharmacy benefit managers and opaque rebate structures.
Merck and Sanofi Join TrumpRx, and the Pressure Campaign Becomes Real
Merck and Sanofi entered TrumpRx as heavyweight validators, not token signers. Their participation expanded the administration’s “most favored nation” pricing push from theory into a rapidly growing list of discounted drugs.
The timeline matters: early waves of agreements came first, then a larger December expansion, with the platform’s debut planned soon after. That sequencing hints at a strategy—stack public commitments, then roll out a shopping-style website.
Merck, Sanofi are latest companies to add medications to TrumpRx https://t.co/zscR6X2RjQ
— FOX Business (@FoxBusiness) April 13, 2026
Patients care about two numbers: the sticker price and the price they actually pay. TrumpRx tries to collapse that gap by offering direct-to-consumer pricing outside the usual insurance maze.
Merck’s diabetes drugs—Januvia and the Janumet line—were cited at roughly 70% discounts, with Januvia reported at around $100 instead of about $330. Sanofi’s average reductions were described around 61% across several categories, with insulin offers framed at $35 per month.
What “Most Favored Nation” Means When It Hits Medicaid
Most favored nation pricing sounds like a trade slogan because it is one: it anchors U.S. prices to lower rates paid in selected developed nations. In the TrumpRx structure, companies reportedly committed to providing Medicaid drugs at benchmarked pricing.
For taxpayers and state budgets, Medicaid is where pricing reforms can move serious money. For manufacturers, Medicaid also creates a hard edge: discounts there can ripple into other pricing formulas and negotiations.
The conservative appeal is obvious: the policy aims at outcomes—lower prices—without building a permanent federal price board that dictates every rate in America.
Voluntary corporate participation, nudged by executive leverage and public scrutiny, aligns better with market instincts than a one-size-fits-all mandate.
The common-sense warning also stands: “voluntary” deals can still become quasi-compulsory if the government stacks incentives and penalties too aggressively. The durability of these commitments will decide which story wins.
Why the Biggest Discounts Don’t Always Mean the Biggest Savings
Some TrumpRx offerings reportedly involve drugs with expired patents, where generics already compete and discounts exist elsewhere. That doesn’t make the program fake; it changes what it’s valuable for.
A platform that bundles options, simplifies access, and posts a cleaner price can still help busy people who don’t have time to hunt for coupons, call pharmacies, or compare discount cards. The risk is mistaking convenience for structural reform.
Look at the attention-grabbing examples: Sanofi’s Plavix price was described as plunging from hundreds of dollars to a startlingly low figure, and other participating companies posted dramatic cuts on specialty drugs.
TrumpRx Versus the Middlemen: A Quiet Fight Over Who Gets Paid
TrumpRx pushes back against the American drug-pricing machine, where list prices, rebates, and negotiated discounts often reward the best negotiators rather than the sickest patients.
Direct-to-consumer pricing threatens the traditional role of pharmacy benefit managers who profit from spread pricing and rebate dynamics that many voters find maddeningly opaque.
If enough patients buy outside the insurance channel, the usual incentive system weakens, and manufacturers may prefer predictable volume at lower margins.
That’s the open loop: drugmakers rarely give up margin unless they gain something else—volume, political goodwill, or protection from harsher regulation.
The administration’s broader bargaining posture reportedly included trade-policy framing and a message that companies should repatriate benefits to American patients.
What to Watch in 2026: Sustainability, Selection, and the Next Nine Companies
By late 2025 reporting, TrumpRx had grown to dozens of drugs across chronic and high-cost categories, with the list expected to expand further. The key question for 2026 isn’t whether the site launches; it’s whether the prices stay low when headlines fade.
Merck, Sanofi are latest companies to add medications to TrumpRx – Fox Business. Check GoodRX and others. https://t.co/8UNFNwvb6Q
— Ed Pageau (@1shaddowman) April 13, 2026
Patients should treat TrumpRx like a new tool, not a miracle. Compare any posted TrumpRx price with a local pharmacy cash price, a discount card, and—if insured—your plan’s copay, because the cheapest path can change month to month.
Policymakers should treat it like a stress test: if voluntary deals and public price posting move the market, the case for heavy-handed price controls weakens. If it fizzles, the pressure for mandates will surge.
Sources:
Merck, Sanofi are latest companies to add medications to TrumpRx
Pharmaceutical Policy in Motion Continued: Trump Inks Nine
TrumpRx signs agreement with nine new pharma manufacturers
TrumpRx drugs: What to know about the discount website
Merck, Sanofi are latest companies to add medications to TrumpRx
